UBS’s Kazia Therapeutics KZIA Stock Holding History

UBS’s Portfolio KZIA Stock Details KZIA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	$3K	Sell	6 -1	-14%	-$642	﹤0.01%	9791
2014 Q2	$5K	Buy	7 +1	+17%	+$768	﹤0.01%	9504
2014 Q1	$5K	Sell	6 -14	-70%	-$11.9K	﹤0.01%	9526
2013 Q4	$17K	Buy	20 +16	+400%	+$15.4K	﹤0.01%	8343
2013 Q3	$4K	Sell	4 -3	-43%	-$2.34K	﹤0.01%	9576
2013 Q2	$6K	Buy	+7	New	+$6.3K	﹤0.01%	9115

Other funds holding KZIA

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

UBS's KZIA Position: Q3 2014 in Review

UBS reduced its Kazia Therapeutics (KZIA) stake by 14% in Q3 2014, selling an estimated $642 and leaving 6 shares worth $3K. The position accounts for ﹤0.01% of the portfolio, ranked #9791.

UBS first reported a position in KZIA in Q2 2013 and has held it in 6 quarters since. The position peaked at $17K in Q4 2013. 5 funds tracked by Wall St. Rank hold KZIA as of Q3 2014.

UBS held 6 shares of Kazia Therapeutics worth $3K as of Q3 2014.
UBS sold 1 Kazia Therapeutics share in Q3 2014, an estimated $642.
Kazia Therapeutics made up ﹤0.01% of UBS's portfolio in Q3 2014, its #9791 holding.
UBS first reported a position in Kazia Therapeutics in Q2 2013 and has held it in 6 quarters since.
UBS's Kazia Therapeutics position peaked at $17K in Q4 2013.
5 funds tracked by Wall St. Rank held Kazia Therapeutics as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.